The strategy of piking a target: What is aktually most effective?

Carlotta Costa; Ana Bosch

doi:10.1158/1078-0432.CCR-17-3440

The strategy of piking a target: What is aktually most effective?

Carlotta Costa, Ana Bosch

Breastcancer-genetics

Research output: Contribution to journal › Article › peer-review

Abstract

Breast and gynecologic cancers harboring PIK3CA mutations showed no significant responses to AZD5363, a pan-AKT catalytic inhibitor, in contrast with previous in vitro data showing activity of the drug in this subset of cancers. These results raise the question of how to select the most accurate predictive biomarkers of response.

Original language	English
Pages (from-to)	2029-2031
Number of pages	3
Journal	Clinical Cancer Research
Volume	24
Issue number	9
DOIs	https://doi.org/10.1158/1078-0432.CCR-17-3440
Publication status	Published - 2018 May 1

Subject classification (UKÄ)

Cancer and Oncology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1158/1078-0432.CCR-17-3440

Cite this

@article{55abbf0995614560857f1642bb585414,

title = "The strategy of piking a target: What is aktually most effective?",

abstract = "Breast and gynecologic cancers harboring PIK3CA mutations showed no significant responses to AZD5363, a pan-AKT catalytic inhibitor, in contrast with previous in vitro data showing activity of the drug in this subset of cancers. These results raise the question of how to select the most accurate predictive biomarkers of response.",

author = "Carlotta Costa and Ana Bosch",

year = "2018",

month = may,

day = "1",

doi = "10.1158/1078-0432.CCR-17-3440",

language = "English",

volume = "24",

pages = "2029--2031",

journal = "Clinical Cancer Research",

issn = "1078-0432",

publisher = "American Association for Cancer Research",

number = "9",

}

TY - JOUR

T1 - The strategy of piking a target

T2 - What is aktually most effective?

AU - Costa, Carlotta

AU - Bosch, Ana

PY - 2018/5/1

Y1 - 2018/5/1

N2 - Breast and gynecologic cancers harboring PIK3CA mutations showed no significant responses to AZD5363, a pan-AKT catalytic inhibitor, in contrast with previous in vitro data showing activity of the drug in this subset of cancers. These results raise the question of how to select the most accurate predictive biomarkers of response.

AB - Breast and gynecologic cancers harboring PIK3CA mutations showed no significant responses to AZD5363, a pan-AKT catalytic inhibitor, in contrast with previous in vitro data showing activity of the drug in this subset of cancers. These results raise the question of how to select the most accurate predictive biomarkers of response.

UR - http://www.scopus.com/inward/record.url?scp=85047831421&partnerID=8YFLogxK

U2 - 10.1158/1078-0432.CCR-17-3440

DO - 10.1158/1078-0432.CCR-17-3440

M3 - Article

C2 - 29374052

AN - SCOPUS:85047831421

SN - 1078-0432

VL - 24

SP - 2029

EP - 2031

JO - Clinical Cancer Research

JF - Clinical Cancer Research

IS - 9

ER -

The strategy of piking a target: What is aktually most effective?

Abstract

Subject classification (UKÄ)

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this